Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Scioderm Inc.
Breakthrough Designation Rescissions: Who Might US FDA Drop Next?
Our chart details the pipeline candidates who might lose the coveted status as treatment paradigms change and trial results come in.
Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure
CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.
Breakthrough Pace Shows No Signs Of Slowing
FDA started off 2016 with a spate of new breakthrough therapy designations, feeding the popular program – and fueling agency concerns about workforce strain.
Pipeline Progress: Highlights Of The J.P. Morgan Conference
Day-by-day updates from the J.P. Morgan Healthcare Conference Jan. 11-14 in San Francisco.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.